NCT03358472 2025-12-03Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)Incyte CorporationPhase 3 Completed89 enrolled 14 charts
NCT02358031 2025-07-18MK-3475-048Merck Sharp & Dohme LLCPhase 3 Completed882 enrolled 50 charts 1 FDA
NCT03342352 2019-12-20Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)Incyte CorporationPhase 3 Withdrawn
NCT03386838 2019-04-18An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and NeckBristol-Myers SquibbPhase 3 Withdrawn